This Curriculum Update addresses the interplay of pathways leading to increased cardiovascular risk. In particular, data suggest that the effects of angiotensin II (Ang II) and lipoproteins on cardiovascular risk are not independent. The following topics are covered in this Curriculum Update:
Published by Medical Education Consultants, Inc. (MEDCON), on behalf of the University of Florida College of Medicine. Supported by an unrestricted educational grant from Pfizer Inc.
The editorial content of this program expresses the views of the individual contributors and does not necessarily reflect the views or recommendations of the University of Florida College of Medicine, Pfizer Inc, or the publisher. The indications and dosages of drugs discussed in this program may vary from those approved by the Food and Drug Administration (FDA). The reader is advised to consult the full prescribing information for each medication prior to use.